Woodline Partners LP Atea Pharmaceuticals, Inc. Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $1.15 Million - $1.92 Million	-208,399 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $177,437 - $1.03 Million	23,134 Added 12.49%	208,399 $1.86 Million
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $54,178 - $89,052	-2,540 Reduced 1.35%	185,265 $6.5 Million
Q2 2021 Aug 16, 2021	SELL	$19.22 - $59.08 $535,622 - $1.65 Million	-27,868 Reduced 12.92%	187,805 $4.03 Million
Q1 2021 May 17, 2021	SELL	$41.42 - $88.44 $2.5 Million - $5.34 Million	-60,410 Reduced 21.88%	215,673 $13.3 Million
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $7.28 Million - $11.5 Million	276,083 New	276,083 $11.5 Million

111

51.2M

71.8K

318K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $286M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.